| Filed On | Filing |
|---|---|
| 23 Apr 2026 |
8-K: Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more
Section 1.1 Registered Office. The corporation shall maintain a registered office and registered agent in the State of Delaware. The registered office and/or registered agent of the corporation may be changed from time to time by action ... |
| 06 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This AGREEMENT AND PLAN OF MERGER, dated as of March 6, 2026 (this “Agreement” and, such date, the “Agreement Date”), by and among Servier Pharmaceuticals LLC, a Delaware limited liability company (“Parent”), Servier Detroit Inc., a Dela... |
| 02 Mar 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Day One Biopharmaceuticals Targeted therapies for people of all ages March 2026 |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Targeted therapies for people of all ages January 2026 Day One Biopharmaceuticals Exhibit 99.3 |
| 06 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more
This Contingent Value Rights Agreement, dated as of January 6, 2026 (this “Agreement”), is entered into by and between Day One Biopharmaceuticals, Inc., a Delaware corporation (“Parent”), and Computershare Inc., a Delaware corporation (“... |
| 24 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.2 Day One Biopharmaceuticals Targeted therapies for people of all ages November 2025 |
| 13 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Targeted therapies for people of all ages November 2025 Day One Biopharmaceuticals |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Commercial execution delivers best quarter launch-to-date with growth across all dimensions of core business |
| 10 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
OJEMDATM (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase |
| 03 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 2, 2025, Day One Biopharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders and the Company’s stockholders voted on and approved the following proposals: |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
OJEMDATM (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 |
| 25 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Achieved Q4 2024 and full year 2024 OJEMDATM (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Exhibit 99.3 Day One Biopharmaceuticals Targeted therapies for people of all ages January 2025 |
| 20 Nov 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 30 Oct 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue |
| 30 Jul 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch |
| 30 Jul 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 30, 2024, by and among Day One Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agre... |
| 25 Jul 2024 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor |
Loading...